Tzield (Teplizumab-mzwv)

TZIELD is a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D.

Dosage and Administration:

Confirm Stage 2 T1D by documenting at least two positive pancreatic islet autoantibodies in those who have dysglycemia without overt hyperglycemia using an oral glucose tolerance test (OGTT) or an alternative method if appropriate and OGTT is not available.

In patients who meet the criteria for a diagnosis of Stage 2 type 1 diabetes, ensure the clinical history of the patient does not suggest type 2 diabetes.

Prior to initiating TZIELD, obtain a complete blood count and liver enzyme tests. Use of TZIELD is not recommended in patients with certain laboratory abnormalities.

Dilute TZIELD in 0.9% Sodium Chloride Injection, USP. Refer to the full prescribing information for detailed preparation and administration instructions.

Premedicate with a nonsteroidal anti-inflammatory drug (NSAID) or acetaminophen, an antihistamine, and/or an antiemetic before each TZIELD dose for at least the first 5 days of the 14-day treatment course.

Administer TZIELD by intravenous infusion (over a minimum of 30 minutes) once daily for 14 days. Please see the full prescribing information for the dosing schedule.

• Cytokine Release Syndrome (CRS): Premedicate, monitor liver enzymes, discontinue in those that develop elevated ALT or AST more than 5 times the upper limit of normal, and if severe CRS develops, consider temporarily pausing dosing.
  
• Serious Infections: Use of TZIELD is not recommended in patients with active serious infection or chronic infection. Monitor for signs and symptoms of infection during and after TZIELD treatment. If a serious infection develops, discontinue TZIELD.
  
• Lymphopenia: Monitor white blood cell counts during the treatment period. If prolonged severe lymphopenia (<500 cells per mcL lasting 1 week or longer) develops, discontinue TZIELD.
  
• Hypersensitivity Reactions: If severe hypersensitivity reactions occur, discontinue TZIELD and treat promptly.
  
• Vaccinations: Administer all age-appropriate vaccinations before starting TZIELD. See recommendations regarding live-attenuated, inactivated, and mRNA vaccines.

If you are considering the import of Tzield (Teplizumab-mzwv) to India, please be aware that Tzield can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

Required Documentation for Import:

• A valid prescription from a qualified medical practitioner.
  
• Diagnostic reports of the patient.
  
• Government-issued identification proof for the patient, as recognized by the Government of India.

The order for Tzield (Teplizumab-mzwv) will be confirmed upon the receipt of the following documents:

• A valid prescription from a qualified doctor.
  
• An import permit, if applicable.

Tzield (Teplizumab-mzwv) is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Tzield can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Tzield (prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

Indian Pharma Network is proficient in sourcing Tzield (Teplizumab-mzwv) from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient’s address, exclusively from New Delhi, India.